Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CX 6526

Next Previous
Drug Profile

CX 6526

Alternative Names: CX-6526

Latest Information Update: 22 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cavion
  • Developer Jazz Pharmaceuticals plc
  • Class Analgesics; Small molecules
  • Mechanism of Action T-type calcium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 22 Feb 2024 CX 6526 is still in phase I trials for Neuropathic pain in the US (Cavion Pipeline, February 2024)
  • 28 Feb 2023 No recent reports of development identified for phase-I development in Neuropathic-pain in USA
  • 03 Jan 2020 Phase-I clinical trials in Neuropathic pain in USA (unspecified route) (Cavion Pharmaceuticals pipeline, January 2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top